From the February 15, 2018 version of this document, “MDL Statistics Report – Distribution of Pending MDL Dockets by Actions Pending” (accessed 2/21/18), published by the United States Judicial Panel on Multidistrict Litigation (JPML), we get the current number of cases filed in each of the four federal court Multidistrict Litigation (MDL) cases for diabetes drugs.
1) IN RE: Incretin-Based Therapies Products Liability Litigation
Number of lawsuits pending in MDL-2452: 936
Primary side effect for these cases:
Pancreatic Cancer / Pancreas Cancer
2) IN RE: Invokana (Canagliflozin) Products Liability Litigation
Number of lawsuits pending in MDL-2750: 985
Primary side effects for these cases:
Diabetic Ketoacidosis (DKA)
Leg Amputation / Foot or Toe(s) Amputation
3) IN RE: Farxiga (Dapagliflozin) Products Liability Litigation
Number of lawsuits pending in MDL-2776: 51
Primary side effect for these cases:
Diabetic Ketoacidosis (DKA)
4) IN RE: Onglyza (Saxagliptin) and Kombiglyze XR (Saxagliptin and Metformin) Products Liability Litigation
Number of lawsuits pending in MDL-2809: 84
Primary side effect for these cases:
Heart Failure
We will continue to monitor the number of pending lawsuits in these four distinct diabetes drugs MDL cases and watch for significant developments in each of these federal court MDL litigations.
[View article at original source]